AI-enhanced adverse event monitoring that detects safety signals across global pharmacovigilance databases with the speed and precision that patient safety demands.
Pharmacovigilance has always been a race between signal emergence and detection. Adverse drug reactions do not announce themselves with clean, unambiguous data. They appear as statistical anomalies buried within millions of individual case safety reports (ICSRs) spanning the FDA’s FAERS database, the EMA’s EudraVigilance system, the WHO’s VigiBase, and proprietary safety databases maintained by marketing authorization holders. Traditional signal detection methods—periodic manual review of disproportionality metrics, scheduled PSUR compilation, and retrospective case series analysis—were designed for an era when reporting volumes were manageable and regulatory expectations were less demanding.
Today, FAERS alone receives over two million adverse event reports annually. EudraVigilance processes comparable volumes across European markets. The mathematical challenge of identifying genuine safety signals within this volume—distinguishing true pharmacological effects from reporting artifacts, confounders, and statistical noise—exceeds the capacity of periodic manual review. Organizations relying on quarterly signal detection cycles routinely discover signals months after they first became statistically detectable, compressing the window for risk mitigation and regulatory response.
Our Pharmacovigilance Signal Detection service deploys a continuous monitoring architecture that ingests data from FAERS, EudraVigilance, VigiBase, published case reports in medical literature, and your proprietary safety databases. We compute a comprehensive suite of disproportionality metrics—proportional reporting ratio (PRR), reporting odds ratio (ROR), empirical Bayesian geometric mean (EBGM), and information component (IC)—on a rolling basis rather than in periodic snapshots. When any metric crosses predefined signal thresholds for a drug-event combination, our system triggers an immediate analytical review.
Signal validation is where domain expertise becomes critical. Not every statistical disproportionality represents a genuine safety signal. Our pharmacovigilance analysts apply structured clinical assessment to each detected signal: evaluating biological plausibility, temporal relationship, dose-response patterns, dechallenge and rechallenge data, and consistency across databases and geographic regions. This structured evaluation eliminates false positives while ensuring that genuine signals are characterized with the analytical rigor required for regulatory communication and risk management decision-making.
Signal detection is only valuable when it connects seamlessly to your regulatory response workflow. Our service is architected to support the complete pharmacovigilance signal management lifecycle: detection, validation, prioritization, evaluation, and regulatory communication. Every confirmed signal is documented in a format compliant with ICH E2E guidelines, CIOMS Working Group standards, and the regulatory expectations of the FDA, EMA, PMDA, and Health Canada.
For organizations with PSMF (Pharmacovigilance System Master File) obligations, our output integrates directly into your signal management procedures. We support the preparation of signal evaluation reports, contribute evidence for Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs), and provide the analytical foundation for Risk Management Plan updates. When a detected signal warrants urgent regulatory communication, we support the preparation of safety variations, Dear Healthcare Professional letters, and risk communication materials with the evidence package regulators expect.
Average signal detection time from data availability to validated safety signal characterization, compared to quarterly cycles in traditional approaches
Rolling disproportionality analysis across all monitored databases with statistical threshold tracking and trend visualization for every drug-event combination under surveillance.
Clinically evaluated signal reports with biological plausibility analysis, evidence grading, ICH E2E-compliant documentation, and recommended pharmacovigilance actions.
Regulatory-ready signal summaries formatted for direct inclusion in Periodic Safety Update Reports and Periodic Benefit-Risk Evaluation Reports.
Real-time visualization of all active and historical signals with filtering by product, event term, database source, disproportionality metric, and signal status.
Systematic monitoring of published case reports, clinical trial publications, and medical literature for emerging safety signals not yet reflected in spontaneous reporting databases.
Evidence packages supporting RMP updates, safety variation submissions, and risk communication materials with the analytical depth regulators expect.
A disciplined four-stage signal detection and management process aligned to ICH E2E guidelines and global pharmacovigilance best practices.
Continuous automated extraction from FAERS, EudraVigilance, VigiBase, medical literature databases, and client proprietary safety systems with standardized MedDRA coding and deduplication.
Rolling computation of PRR, ROR, EBGM, and IC metrics across all monitored drug-event combinations with configurable threshold alerting and trend analysis.
Structured clinical assessment of detected signals evaluating biological plausibility, temporal relationship, dose-response, and cross-database consistency to eliminate false positives.
ICH-compliant signal documentation, priority classification, and regulatory submission support including PSUR contributions, RMP updates, and urgent safety communications.
Patient safety depends on the speed and quality of your pharmacovigilance signal detection. Our continuous monitoring closes the gap between signal emergence and organizational awareness.
Schedule a PV Consultation